The drug clinical trial application for Human Umbilical Cord Mesenchymal Stem Cell Type II Injection, submitted by Zhejiang Wolwo Stem Cell Technology, an indirectly controlled subsidiary of Wolwo Bio, has been formally accepted by the National Medical Products Administration. The product is a Class 1 therapeutic biological product, indicated for sepsis and/or septic shock. Currently, no similar mesenchymal stem cell drug has been approved for marketing either domestically or internationally. The company stated that this acceptance marks an important R&D milestone in the stem cell drug field. In the first quarter of 2026, Wolwo Bio achieved revenue of 253 million yuan and net profit attributable to the parent of 119 million yuan.
Zhejiang Wolwo Bio-Pharmaceutical Co LtdClinical trial application for a novel stem cell drug accepted, a key R&D milestone.
Subsidiary's drug application accepted, marking progress in stem cell drug development.